Merck & Co. Inc. / Verona Pharma plc

Chronic Obstructive Pulmonary Disease (COPD)

16M US cases/yr · $18.5B Global COPD market 2024 · ~$49B Annual US economic burden

Disease Overview

Chronic obstructive pulmonary disease (COPD) is a progressive, heterogeneous inflammatory lung disease characterized by persistent airflow limitation arising from a mixture of small airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema). Cigarette smoking remains the predominant cause in high-income countries, with biomass fuel exposure, occupational dusts and childhood respiratory infections contributing globally. Patients experience chronic dyspnea, cough, sputum production and punctuating acute exacerbations that accelerate lung function decline, drive hospitalization and increase mortality. COPD is the fourth leading cause of death in the United States and a leading cause of Medicare spending. Disease assessment relies on post-bronchodilator spirometry (FEV1/FVC <0.70), symptom scales (CAT, mMRC) and exacerbation history, which together stratify patients into GOLD A-E groups guiding escalation from short-acting bronchodilators through LAMA/LABA dual therapy to triple ICS/LAMA/LABA combinations. Despite maximal inhaled therapy, many patients remain symptomatic and continue to exacerbate, underscoring a decades-long unmet need for novel mechanisms that address both bronchodilation and non-type-2 inflammation.

Competitive Landscape

The COPD maintenance landscape remains anchored on three inhaled bronchodilator/anti-inflammatory mechanisms layered into mono-, dual- and triple-therapy devices. LAMA agents include tiotropium (Spiriva, Boehringer Ingelheim), umeclidinium (Incruse, GSK), glycopyrrolate (Seebri) and aclidinium. LABA agents include salmeterol (Serevent), formoterol, olodaterol (Striverdi) and vilanterol. Key LAMA/LABA combinations are Anoro Ellipta (umeclidinium/vilanterol, GSK), Stiolto Respimat (tiotropium/olodaterol, Boehringer) and Bevespi (glycopyrrolate/formoterol, AstraZeneca). Triple ICS/LAMA/LABA inhalers include Trelegy Ellipta (fluticasone/umeclidinium/vilanterol, GSK) and Breztri Aerosphere (budesonide/glycopyrronium/formoterol, AstraZeneca). Biologic entrants targeting type-2 inflammation now include dupilumab (Dupixent, Regeneron/Sanofi, IL-4/IL-13, approved Sep 2024 for eosinophilic COPD) and mepolizumab (Nucala, GSK, IL-5, approved May 2025). Ohtuvayre (ensifentrine, Verona/Merck) became the first novel inhaled mechanism in over two decades upon its June 2024 FDA approval, delivering combined bronchodilation and non-steroidal anti-inflammatory activity via dual PDE3/PDE4 inhibition. Pipeline mechanisms include itepekimab (IL-33, Regeneron/Sanofi Ph3), tozorakimab (IL-33, AstraZeneca) and astegolimab (ST2, Roche/Amgen).